Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Splenic marginal zone B-cell

Splenic marginal zone B-cell lymphoma regularly involves the spleen, often bone marrow, and more rarely the peripheral lymph nodes. The disease may be dominated by anemia caused by autoimmunity, splenomegaly and/or marrow repression.

Patients may live long with this disease.


The goal of treatment is to prolong survival with a palliative effect. A splenectomy is often indicated as the first treatment choice having a therapeutic effect as well as improving a possible hemolytic condition. 

The effect of chemotherapy is poorer than for chronic lymphatic leukemia/lymphoma, but the effect of rituximab is good, given either alone or combined with chemotherapy (retrospective study). 

The treatment principles are the same as for other B-cell lymphomas with low aggressiveness. This means that depending on age, comorbidity and disease aggressiveness, a choice can be made between rituximab monotherapy, chlorambucil, or C(H)OP and rituximab. Interferon-alpha-2-beta has been shown to provide good response in this group of lymphoma patients who are also hepatitis C positive. 

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2017